BRIEF—ONO and Bristol-Myers to market Opdivo/Yervoy combo in Japan

Japan’s ONO Pharmaceutical and New York's Bristol-Myers Squibb have successfully expanded the Japanese labels for Opdivo (nivolumab) and Yervoy (ipilimumab), to be used in combination against unresectable melanoma.

Both Opdivo and Yervoy have been approved for the treatment of unresectable melanoma as monotherapy. The extension to allow their use in combination was based on positive data from the Phase II ONO-4538-17 and Phase III CheckMate-067 trials.